eprintid: 10184137 rev_number: 6 eprint_status: archive userid: 699 dir: disk0/10/18/41/37 datestamp: 2023-12-19 10:55:38 lastmod: 2023-12-19 10:55:38 status_changed: 2023-12-19 10:55:38 type: article metadata_visibility: show sword_depositor: 699 creators_name: Ogbe, A creators_name: Pace, M creators_name: Bittaye, M creators_name: Tipoe, T creators_name: Adele, S creators_name: Alagaratnam, J creators_name: Aley, PK creators_name: Ansari, MA creators_name: Bara, A creators_name: Broadhead, S creators_name: Brown, A creators_name: Brown, H creators_name: Cappuccini, F creators_name: Cinardo, P creators_name: Dejnirattisai, W creators_name: Ewer, KJ creators_name: Fok, H creators_name: Folegatti, PM creators_name: Fowler, J creators_name: Godfrey, L creators_name: Goodman, AL creators_name: Jackson, B creators_name: Jenkin, D creators_name: Jones, M creators_name: Longet, S creators_name: Makinson, RA creators_name: Marchevsky, NG creators_name: Mathew, M creators_name: Mazzella, A creators_name: Mujadidi, YF creators_name: Parolini, L creators_name: Petersen, C creators_name: Plested, E creators_name: Pollock, KM creators_name: Rajeswaran, T creators_name: Ramasamy, MN creators_name: Rhead, S creators_name: Robinson, H creators_name: Robinson, N creators_name: Sanders, H creators_name: Serrano, S creators_name: Tipton, T creators_name: Waters, A creators_name: Zacharopoulou, P creators_name: Barnes, E creators_name: Dunachie, S creators_name: Goulder, P creators_name: Klenerman, P creators_name: Screaton, GR creators_name: Winston, A creators_name: Hill, AVS creators_name: Gilbert, SC creators_name: Carroll, M creators_name: Pollard, AJ creators_name: Fidler, S creators_name: Fox, J creators_name: Lambe, T creators_name: Frater, J title: Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV ispublished: pub divisions: UCL divisions: B02 divisions: D65 divisions: J38 keywords: AIDS/HIV, Adaptive immunity, COVID-19, Cellular immune response, T cells, COVID-19, ChAdOx1 nCoV-19, HIV Infections, Humans, Male, SARS-CoV-2, Vaccination note: Copyright: © 2022, Ogbe et al. This is an open access article published under the terms of the Creative CommonsAttribution 4.0 International License. abstract: Duration of protection from SARS-CoV-2 infection in people living with HIV (PWH) following vaccination is unclear. In a substudy of the phase II/III the COV002 trial (NCT04400838), 54 HIV+ male participants on antiretroviral therapy (undetectable viral loads, CD4+ T cells > 350 cells/μL) received 2 doses of ChAdOx1 nCoV-19 (AZD1222) 4-6 weeks apart and were followed for 6 months. Responses to vaccination were determined by serology (IgG ELISA and Meso Scale Discovery [MSD]), neutralization, ACE-2 inhibition, IFN-γ ELISpot, activation-induced marker (AIM) assay and T cell proliferation. We show that, 6 months after vaccination, the majority of measurable immune responses were greater than prevaccination baseline but with evidence of a decline in both humoral and cell-mediated immunity. There was, however, no significant difference compared with a cohort of HIV-uninfected individuals vaccinated with the same regimen. Responses to the variants of concern were detectable, although they were lower than WT. Preexisting cross-reactive T cell responses to SARS-CoV-2 spike were associated with greater postvaccine immunity and correlated with prior exposure to beta coronaviruses. These data support the ongoing policy to vaccinate PWH against SARS-CoV-2, and they underpin the need for long-term monitoring of responses after vaccination. date: 2022-04-08 date_type: published publisher: American Society for Clinical Investigation official_url: https://doi.org/10.1172/jci.insight.157031 oa_status: green full_text_type: pub language: eng primo: open primo_central: open_green verified: verified_manual elements_id: 1952130 doi: 10.1172/jci.insight.157031 medium: Electronic pii: 157031 lyricists_name: Goodman, Anna lyricists_id: ALGOO97 actors_name: Goodman, Anna actors_id: ALGOO97 actors_role: owner funding_acknowledgements: [Wellcome Trust]; MC_UU_00004/04 [Medical Research Council]; MR/L006588/1 [Medical Research Council]; MR/P011233/1 [Medical Research Council] full_text_status: public publication: JCI Insight volume: 7 number: 7 article_number: e157031 event_location: United States issn: 2379-3708 citation: Ogbe, A; Pace, M; Bittaye, M; Tipoe, T; Adele, S; Alagaratnam, J; Aley, PK; ... Frater, J; + view all <#> Ogbe, A; Pace, M; Bittaye, M; Tipoe, T; Adele, S; Alagaratnam, J; Aley, PK; Ansari, MA; Bara, A; Broadhead, S; Brown, A; Brown, H; Cappuccini, F; Cinardo, P; Dejnirattisai, W; Ewer, KJ; Fok, H; Folegatti, PM; Fowler, J; Godfrey, L; Goodman, AL; Jackson, B; Jenkin, D; Jones, M; Longet, S; Makinson, RA; Marchevsky, NG; Mathew, M; Mazzella, A; Mujadidi, YF; Parolini, L; Petersen, C; Plested, E; Pollock, KM; Rajeswaran, T; Ramasamy, MN; Rhead, S; Robinson, H; Robinson, N; Sanders, H; Serrano, S; Tipton, T; Waters, A; Zacharopoulou, P; Barnes, E; Dunachie, S; Goulder, P; Klenerman, P; Screaton, GR; Winston, A; Hill, AVS; Gilbert, SC; Carroll, M; Pollard, AJ; Fidler, S; Fox, J; Lambe, T; Frater, J; - view fewer <#> (2022) Durability of ChAdOx1 nCoV-19 vaccination in people living with HIV. JCI Insight , 7 (7) , Article e157031. 10.1172/jci.insight.157031 <https://doi.org/10.1172/jci.insight.157031>. Green open access document_url: https://discovery.ucl.ac.uk/id/eprint/10184137/1/Durability%20of%20ChAdOx1%20nCoV-19%20vaccination%20in%20people%20living%20with%20HIV.pdf